Enoxaparin more cost-effective than UFH in fibrinolysis for STEMI
Links shared publicly online about this topic.
- 1,729total visits
Enoxaparin more cost-effective than UFH in fibrinolysis for STEMI
A new analysis of the EXTRACT-TIMI 25 trial concludes that enoxaparin is slightly cheaper in the long term than unfractionated heparin for STEMI patients undergoing thrombolysis. But there are questions as to why 30-day data and not one-year results were used to model long-term cost-effectiveness.
View full resource at theheart.org
Tags: Deep Venous Thrombosis Medication, Lovenox, Clexane
Most Recently Shared on September 22, 2009 at 10:16 pm By:
heartwire: Enoxaparin cheaper than UFH in STEMI patients undergoing thrombolysis? http://bit.ly/29orY9
Advertisement
